Comparative Pharmacology
Head-to-head clinical analysis: LYNAVOY versus UVADEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYNAVOY versus UVADEX.
LYNAVOY vs UVADEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYNAVOY (mirdametinib) is an oral, reversible, allosteric inhibitor of MEK1 and MEK2, blocking downstream MAPK/ERK signaling pathway activation, thereby inhibiting tumor cell proliferation and survival.
Uvadex, when combined with UVA light, intercalates into DNA and upon UVA activation forms covalent cross-links with pyrimidine bases, thereby inhibiting DNA synthesis and inducing apoptosis in activated T-cells.
LYNAVOY (vitrakvi, larotrectinib) 100 mg orally twice daily, with or without food, until disease progression or unacceptable toxicity. For patients with body surface area <1.0 m2, the recommended dose is 100 mg/m2 per dose (maximum 100 mg per dose) twice daily.
200 mcg/mL solution administered via intravenous injection 0.017 mL/kg (3.4 mcg/kg) 30 minutes prior to each photopheresis treatment, given on two consecutive days every 2–4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 30–40 hours, supporting once-daily dosing. Steady-state is achieved within 2–3 weeks.
Terminal elimination half-life is approximately 12 hours (range 8-20 hours) following intravenous administration; clinically, this supports daily dosing schedules.
Primarily via bile into feces (approximately 77% of total clearance as unchanged drug and metabolites); renal excretion accounts for about 15% (less than 1% unchanged). A small amount is excreted in urine as metabolites.
Primarily renal excretion of unchanged drug (approximately 70% within 24 hours) and metabolites; minor fecal elimination (<10%).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent